Much of Graham's weakness has been triggered by the Q3 results, and also some concerns over global shipbuilding momentum.

Tim Friede has been bitten by hundreds of snakes. And now, scientists are studying his blood to create a universal antivenom.

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

Me declared bankruptcy and announced they are selling the company, including the massive amounts of data it has collected ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Whether or not Elon Musk scales down his role in Washington, it appears his empire stands to gain from his meddling in ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Microbial biotechnology has emerged as a promising area in the production of food coloring, flavoring, and fragrance, driven by the pressing need for ...

The National Security Commission on Emerging Biotechnology (NSCEB) announced on April 8, 2025, the availability of its final report and action plan, “urging Congressional action to bring the full ...

Noticing a growth in venture capital-funded startups in the biosciences sector, the Health Sciences & Services Authority of ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T-cell ...